Abcam Plc expect to report revenue growth of approximately 28%, or 30% for the sic months period ended December 31, 2012, on a constant currency basis, which, taking into account the unaudited revenues of Epitomics and Ascent for the same period last year, represents underlying growth at constant currency of just over 12%.